Downloaded from http://bjo.bmj.com/ on June 15, 2015 - Published by group.bmj.com

BJO Online First, published on April 16, 2015 as 10.1136/bjophthalmol-2014-306417 Clinical science

Changes in choroidal thickness after intravitreal dexamethasone implant injection in retinal vein occlusion Eun Kyoung Lee,1 Jeong Mo Han,1 Joon Young Hyon,2 Hyeong Gon Yu1 1

Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea 2 Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea Correspondence to Dr Hyeong Gon Yu, Department of Ophthalmology, Seoul National University Hospital, #101, Daehak-ro, Jongno-gu, Seoul 110-744, South Korea; [email protected] EKL and JMH contributed equally to the work. Received 17 November 2014 Accepted 1 April 2015

ABSTRACT Aims To investigate the choroidal thickness changes in eyes with retinal vein occlusion (RVO) and to determine the effect of an intravitreal dexamethasone implant (Ozurdex) on choroidal thickness. Methods This study comprised 47 patients diagnosed with unilateral, RVO-associated macular oedema (MO) and treated with Ozurdex. Baseline subfoveal choroidal thickness (SFCT) and central macular thickness (CMT) of the RVO eyes were compared with those of the normal contralateral eyes; serial changes in this parameter were evaluated at 1, 3 and 5 months after Ozurdex injection. The correlation between SFCT and CMT and between visual acuity change and SFCT or CMT changes were also investigated. Results The mean SFCT was significantly higher in RVO eyes at baseline (260.3±71.2 μm) than it was in contralateral eyes (217.6±55.3 μm; p